Abstract:We established proof of concept for activating pyruvate kinase in sickle cell disease (SCD) as a viable therapeutic approach. Mitapivat, a PK activator, improved hematologic parameters, increased oxygen affinity, and reduced sickling in patients with SCD anemia. Polymerization of deoxygenated hemoglobin S (HbS) underlies the pathophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. Both changes have therapeutic potential for patients with SCD. Here, we evaluated the safety and tolerability of multiple ascending doses of mitapivat in adults with SCD (HbSS) with no recent blood transfusions or changes in hydroxyurea (HU) or L-glutamine therapy. Seventeen subjects were enrolled, 1 subject was withdrawn shortly after starting the study. Sixteen subjects completed 3 ascending dose levels of mitapivat (5 mg, 20 mg and 50 mg, twice daily (BID)) for 2 weeks each; following a protocol amendment, the dose was escalated to 100 mg BID in 9 subjects. Mitapivat was well-tolerated at all dose levels, with the most common treatment-emergent adverse events (AEs) being insomnia, headache, and hypertension. Six serious AEs (SAEs) included 4 vaso-occlusive crises (VOCs), non-VOC-related shoulder pain, and a pre-existing pulmonary embolism. Two VOCs occurred during drug taper and were possibly drug-related; no other SAEs were drug-related. Mean hemoglobin increase at the 50 mg BID dose level was 1.2 g/dL, with 9/16 (56.3%) patients achieving a hemoglobin response of ≥ 1 g/dL increase compared to baseline. Mean reductions in hemolytic markers and dose-dependent decreases in 2,3-DPG and increases in ATP were also observed. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. (Investigator-sponsor; ClinicalTrials.gov NCT04000165).

Pyruvate kinase activators: targeting red cell metabolism in thalassemia

Erythrocyte pyruvate kinase activation in red cell disorders

P1565: Mitapivat Improves Ineffective Erythropoiesis And Reduces Iron Overload In Patients With Pyruvate Kinase Deficiency

How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency

Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation.

A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease

Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease

Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency

Therapeutic Relevance of Inducing Autophagy in β-Thalassemia

Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease

Novel Therapeutic Approaches In Thalassemias, Sickle Cell Disease And Other Red Cell Disorders

Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults

Apohemoglobin-haptoglobin complex alleviates iron toxicity in mice with β-thalassemia via scavenging of cell-free hemoglobin and heme

The search for pyruvate kinase-R activators; from a HTS screening hit via an impurity to the discovery of a lead series

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Dual α-globin and truncated EPO receptor knockin restores hemoglobin production in α-thalassemia-derived red blood cells

Investigational drugs in phase I and phase II clinical trials for thalassemia

[Overview of new approaches to β-thalassemia treatment]

The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia

Beyond adenosine triphosphate: unveiling the pleiotropic effects of pyruvate kinase activation in sickle cell anemia

Oxidative Stress in β-Thalassemia